Aparajita Lath Immunization Intellectual Property Pharmaceuticals Public Health Student Fellows Vaccines
mRNA
-
-
Aparajita Lath Global Health Health Law Policy Intellectual Property Market Design Pharmaceuticals Public Health Reimbursement Resource Allocation Student Fellows VaccinesUnlocking the mRNA Platform Technology: Walking the Talk with Investment Protection
Read more: Unlocking the mRNA Platform Technology: Walking the Talk with Investment Protection -
Aparajita Lath Featured Global Health Health Law Policy Intellectual Property Pharmaceuticals Student Fellows VaccinesThe Secret World of mRNA: HDT Bio Corp v. Emcure and Access to Next-Gen mRNA
Read more: The Secret World of mRNA: HDT Bio Corp v. Emcure and Access to Next-Gen mRNA -
Aparajita Lath Biotechnology Health Law Policy Intellectual Property International Pharmaceuticals Public Health Resource Allocation Student Fellows VaccinesAccessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’
Read more: Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’ -
Biotechnology Featured Genetics Health Information Technology History Intellectual Property Jorge Contreras Research Funding Scientific Evidence Supreme Court VaccinesWill NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?
Read more: Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna? -
Contributors FDA Health Law Policy Human Subjects Research Immunization Jacob Sherkow Nicholson Price Pharmaceuticals Public Health Rachel Sachs Scientific Evidence VaccinesWhy Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines?
Read more: Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines? -
Contributors FDA Health Law Policy Jacob Sherkow Nicholson Price Pharmaceuticals Public Health Rachel Sachs VaccinesWhat’s the Difference Between Vaccine Approval (BLA) and Authorization (EUA)?
Read more: What’s the Difference Between Vaccine Approval (BLA) and Authorization (EUA)? -
Contributors FDA Health Law Policy Jacob Sherkow Nicholson Price Patient Care Pharmaceuticals Public Health Rachel Sachs VaccinesHow Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing?
Read more: How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing? -
Contributors FDA Health Law Policy Jacob Sherkow Nicholson Price Patient Care Pharmaceuticals Public Health Rachel Sachs VaccinesWhy Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19?
Read more: Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19? -
Contributors FDA Health Law Policy Jacob Sherkow Nicholson Price Patient Care Pharmaceuticals Public Health Rachel Sachs VaccinesWhat Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout?
Read more: What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout?